Pear Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019
Net Income	-75.49	-65.14	-108.08	-9.33
Depreciation & Amortization	5.7	2.25	0.43	0.21
Share-Based Compensation	13.53	3.81	9.03	1.28
Other Operating Activities	-57.64	-49.96	19.67	-28.75
Operating Cash Flow	-113.9	-109.04	-67.89	-36.6
Capital Expenditures	-3.47	-3.28	-3.9	-0.28
Change in Investments	-5.99	8.51	63.58	-40.28
Other Investing Activities	-	-2.35	-0.75	-
Investing Cash Flow	-9.46	2.88	58.93	-40.56
Share Issuance / Repurchase	2.16	145.16	0.41	0.1
Debt Issued / Paid	0	-1	12.22	12.51
Other Financing Activities	-	19.92	79.07	0.05
Financing Cash Flow	2.16	164.08	91.7	12.66
Net Cash Flow	-121.2	57.92	82.73	64.5
Free Cash Flow	-117.37	-112.32	-71.79	-36.88
Free Cash Flow Margin	-924.57%	-2669.23%	-765.07%	-113.25%
Free Cash Flow Per Share	-0.85	-0.99	-0.81	-2.50

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).